Psilocybin could soon help millions of people tackle obesity and eating disorders.After all, the global obesity epidemic is still bursting at the seams. According to the World Health Organization obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adults were overweight around the world. Of those, 650 million were considered obese. Just in the U.S., nearly 34% of adults and up to 20% …
Psilocybin could soon help millions of people tackle obesity and eating disorders.
After all, the global obesity epidemic is still bursting at the seams.
According to the World Health Organization (WHO) obesity has tripled in size over the last 50 years. In 2016, they note, 1.9 billion adults were overweight around the world. Of those, 650 million were considered obese. Just in the U.S., nearly 34% of adults and up to 20% of children are obese. By 2030, almost half of U.S. adults will be considered obese.
However, a solution may be found in psychedelics such as psilocybin, which activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.”
Psychedelics, like psilocybin are going mainstream
Denver, Oakland, and Santa Cruz have already legalized its use. Joining them, Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mushrooms, as well. In addition, a ballot in Oregon could legalize its use by November 2020.
Better, such drugs are already proving to be a major game changer for millions of people all over the world. Countless studies are already proving such treatments can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. Plus, with plenty of clinical trials supporting psychedelic treatments, it’s only a matter of time before big pharmaceutical companies begin to invest heavily and incorporate psychedelics into their own drug pipelines.
Better Plant Sciences’ (CSE: PLNT) (OTC: VEGGF) NeonMind Could Help Lead the Way
Better Plant Sciences’ majority owned subsidiary NeonMind Biosciences just entered into a definitive agreement with Psygen Labs Inc. for the supply of psilocybin for NeonMind’s planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety.
“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind, “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”
“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem. Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”
For more information, visit the company’s website at https://betterplantsciences.com
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64929
News Provided by Newsfile via QuoteMedia